These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8796275)
21. The clearance rate of plasma kallikrein by the liver increases during the acute-phase response to inflammation. Martins B; Kouyoumdjian M; Limaos EA; Borges DR Agents Actions; 1992 Sep; 37(1-2):111-3. PubMed ID: 1456171 [TBL] [Abstract][Full Text] [Related]
22. Chronic administration of ethanol does not alter plasma kallikrein hepatic clearance. Toledo CF; Borges DR Braz J Med Biol Res; 1990; 23(5):409-15. PubMed ID: 2095290 [TBL] [Abstract][Full Text] [Related]
23. The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator. Kaneko M; Mimuro J; Matsuda M; Sakata Y Biochem Biophys Res Commun; 1991 Aug; 178(3):1160-6. PubMed ID: 1908232 [TBL] [Abstract][Full Text] [Related]
24. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Edelberg JM; Gonzalez-Gronow M; Pizzo SV Thromb Res; 1990 Jan; 57(1):155-62. PubMed ID: 2137266 [No Abstract] [Full Text] [Related]
25. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. Rajapakse S; Ogiwara K; Takano N; Moriyama A; Takahashi T FEBS Lett; 2005 Dec; 579(30):6879-84. PubMed ID: 16337200 [TBL] [Abstract][Full Text] [Related]
26. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Mars WM; Zarnegar R; Michalopoulos GK Am J Pathol; 1993 Sep; 143(3):949-58. PubMed ID: 8362987 [TBL] [Abstract][Full Text] [Related]
27. Tissue plasminogen activator is endocytosed by mannose and galactose receptors of rat liver cells. Smedsrød B; Einarsson M; Pertoft H Thromb Haemost; 1988 Jun; 59(3):480-4. PubMed ID: 2847350 [TBL] [Abstract][Full Text] [Related]
28. Effects of epsilon-aminocaproiloaminoacids on the amidolytic activity of tissue plasminogen activator, urokinase and kallikrein. Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Markowska A Acta Pol Pharm; 2004; 61(1):75-6. PubMed ID: 15259861 [TBL] [Abstract][Full Text] [Related]
29. Chloramine T impairs the receptor-mediated endocytosis of plasma kallikrein by the liver. Borges DR; Kouyoumdjian M Agents Actions Suppl; 1992; 38 ( Pt 2)():278-84. PubMed ID: 1462833 [TBL] [Abstract][Full Text] [Related]
30. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia. Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840 [TBL] [Abstract][Full Text] [Related]
31. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator. Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237 [TBL] [Abstract][Full Text] [Related]
32. Tissue-type plasminogen activator release: new frontiers in endothelial function. Muldowney JA; Vaughan DE J Am Coll Cardiol; 2002 Sep; 40(5):967-9. PubMed ID: 12225724 [No Abstract] [Full Text] [Related]
33. Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA. Otter M; Kuiper J; Bos R; Rijken DC; van Berkel TJ Biochem J; 1992 Jun; 284 ( Pt 2)(Pt 2):545-50. PubMed ID: 1318035 [TBL] [Abstract][Full Text] [Related]
34. Native plasma kallikrein is cleared at similar rates by mammalian and avian livers. Borges DR; Kouyoumdjian M; Limãos EA Braz J Med Biol Res; 1991; 24(1):63-5. PubMed ID: 1823219 [TBL] [Abstract][Full Text] [Related]
35. Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications. Cohen AF; Burggraaf K; de Boer A; Kluft C Ann N Y Acad Sci; 1992 Dec; 667():443-9. PubMed ID: 1309067 [No Abstract] [Full Text] [Related]
36. Binding and degradation of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Otter M; Van Berkel TJ; Rijken DC Thromb Haemost; 1989 Sep; 62(2):667-72. PubMed ID: 2510347 [TBL] [Abstract][Full Text] [Related]
37. Induction of hepatic tissue-type plasminogen activator and type 1 plasminogen activator-inhibitor gene expressions and appearance of their translation products in the bile following acute liver injury in rats. Noguchi T; Matsuyama S; Akao M; Hagiwara H; Uno S; Seki T; Ariga T Thromb Res; 2001 Nov; 104(4):283-91. PubMed ID: 11728530 [TBL] [Abstract][Full Text] [Related]
38. Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome. Brus F; van Oeveren W; Okken A; Oetomo SB Pediatr Res; 1994 Nov; 36(5):647-53. PubMed ID: 7877886 [TBL] [Abstract][Full Text] [Related]
39. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
40. Characterization of the murine plasma fibrinolytic system. Lijnen HR; van Hoef B; Beelen V; Collen D Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]